Human BSPII Protein

BSP-HM101 Cat. No.



Description	
Source	Recombinant Human BSPII Protein is expressed from HEK293 with His tag at the C-Terminus.
	It contains Phe17-Gln317.
Accession	P21815
Molecular Weight	The protein has a predicted MW of 34.3 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE
	> 95% as determined by HPLC


Formulation and Storage		
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.	
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.	
Storage	-20 to -80°C for 12 months as supplied from date of receipt20 to -80°C for 3-6 months in unopened state after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles	

Background

IBSP (Integrin Binding Sialoprotein) is a Protein Coding gene. Diseases associated with IBSP include Fibrous Dysplasia and Chondromalacia. Among its related pathways are Degradation of the extracellular matrix and Cytoskeletal Signaling. The protein encoded by this gene is a major structural protein of the bone matrix. It constitutes approximately 12% of the noncollagenous proteins in human bone and is synthesized by skeletalassociated cell types, including hypertrophic chondrocytes, osteoblasts, osteocytes, and osteoclasts.

Assay Data

Tris-Bis PAGE




Human BSPII on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Cat. No. BSP-HM101



Assay Data



The purity of Human BSPII is greater than 95% as determined by SEC-HPLC.